PARS2

Across TCGA pan-cancer cohorts, PARS2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PARS2 data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PARS2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PARS2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where PARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	1.000	0.755	.010	12	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
LSCC	DFS	Median	II,III,IV	0.451	0.877	.044	2	view →
LUAD	OS	Quartile	III,IV	1.000	0.340	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PARS2–CCRCC (OS)

Open the CCRCC breakdown →